Cargando…

Allele Copy Number and Underlying Pathology Are Associated with Subclinical Severity in Equine Type 1 Polysaccharide Storage Myopathy (PSSM1)

Equine type 1 polysaccharide storage myopathy (PSSM1), a common glycogenosis associated with an R309H founder mutation in the glycogen synthase 1 gene (GYS1), shares pathological features with several human myopathies. In common with related human disorders, the pathogenesis remains unclear in parti...

Descripción completa

Detalles Bibliográficos
Autores principales: Naylor, Rosie J., Livesey, Leanda, Schumacher, John, Henke, Nicole, Massey, Claire, Brock, Kenny V., Fernandez-Fuente, Marta, Piercy, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409190/
https://www.ncbi.nlm.nih.gov/pubmed/22860112
http://dx.doi.org/10.1371/journal.pone.0042317
_version_ 1782239555566436352
author Naylor, Rosie J.
Livesey, Leanda
Schumacher, John
Henke, Nicole
Massey, Claire
Brock, Kenny V.
Fernandez-Fuente, Marta
Piercy, Richard J.
author_facet Naylor, Rosie J.
Livesey, Leanda
Schumacher, John
Henke, Nicole
Massey, Claire
Brock, Kenny V.
Fernandez-Fuente, Marta
Piercy, Richard J.
author_sort Naylor, Rosie J.
collection PubMed
description Equine type 1 polysaccharide storage myopathy (PSSM1), a common glycogenosis associated with an R309H founder mutation in the glycogen synthase 1 gene (GYS1), shares pathological features with several human myopathies. In common with related human disorders, the pathogenesis remains unclear in particular, the marked phenotypic variability between affected animals. Given that affected animals accumulate glycogen and alpha-crystalline polysaccharide within their muscles, it is possible that physical disruption associated with the presence of this material could exacerbate the phenotype. The aim of this study was to compare the histopathological changes in horses with PSSM1, and specifically, to investigate the hypothesis that the severity of underlying pathology, (e.g. vacuolation and inclusion formation) would (1) be higher in homozygotes than heterozygotes and (2) correlate with clinical severity. Resting and post-exercise plasma creatine kinase (CK) and aspartate aminotransferase (AST) enzyme activity measurements and muscle pathology were assessed in matched cohorts of PSSM1 homozygotes, heterozygotes or control horses. Median (interquartile range (IR)) resting CK activities were 364 (332–764) U/L for homozygotes, 301 (222–377) U/L for heterozygotes and 260 (216–320) U/L for controls, and mean (+/− SD) AST activity for homozygotes were 502 (+/116) U/L, for heterozygotes, 357 (+/−92) U/L and for controls, 311 (+/−64) U/L and were significantly different between groups (P = 0.04 and P = 0.01 respectively). Resting plasma AST activity was significantly associated with the severity of subsarcolemmal vacuolation (rho = 0.816; P = 0.01) and cytoplasmic inclusions (rho = 0.766; P = 0.01). There were fewer type 2× and more type 2a muscle fibres in PSSM1-affected horses. Our results indicate that PSSM1 has incomplete dominance. Furthermore, the association between plasma muscle enzyme activity and severity of underlying pathology suggests that physical disruption of myofibres may contribute to the myopathic phenotype. This work provides insight into PSSM1 pathogenesis and has implications for related human glycogenoses.
format Online
Article
Text
id pubmed-3409190
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34091902012-08-02 Allele Copy Number and Underlying Pathology Are Associated with Subclinical Severity in Equine Type 1 Polysaccharide Storage Myopathy (PSSM1) Naylor, Rosie J. Livesey, Leanda Schumacher, John Henke, Nicole Massey, Claire Brock, Kenny V. Fernandez-Fuente, Marta Piercy, Richard J. PLoS One Research Article Equine type 1 polysaccharide storage myopathy (PSSM1), a common glycogenosis associated with an R309H founder mutation in the glycogen synthase 1 gene (GYS1), shares pathological features with several human myopathies. In common with related human disorders, the pathogenesis remains unclear in particular, the marked phenotypic variability between affected animals. Given that affected animals accumulate glycogen and alpha-crystalline polysaccharide within their muscles, it is possible that physical disruption associated with the presence of this material could exacerbate the phenotype. The aim of this study was to compare the histopathological changes in horses with PSSM1, and specifically, to investigate the hypothesis that the severity of underlying pathology, (e.g. vacuolation and inclusion formation) would (1) be higher in homozygotes than heterozygotes and (2) correlate with clinical severity. Resting and post-exercise plasma creatine kinase (CK) and aspartate aminotransferase (AST) enzyme activity measurements and muscle pathology were assessed in matched cohorts of PSSM1 homozygotes, heterozygotes or control horses. Median (interquartile range (IR)) resting CK activities were 364 (332–764) U/L for homozygotes, 301 (222–377) U/L for heterozygotes and 260 (216–320) U/L for controls, and mean (+/− SD) AST activity for homozygotes were 502 (+/116) U/L, for heterozygotes, 357 (+/−92) U/L and for controls, 311 (+/−64) U/L and were significantly different between groups (P = 0.04 and P = 0.01 respectively). Resting plasma AST activity was significantly associated with the severity of subsarcolemmal vacuolation (rho = 0.816; P = 0.01) and cytoplasmic inclusions (rho = 0.766; P = 0.01). There were fewer type 2× and more type 2a muscle fibres in PSSM1-affected horses. Our results indicate that PSSM1 has incomplete dominance. Furthermore, the association between plasma muscle enzyme activity and severity of underlying pathology suggests that physical disruption of myofibres may contribute to the myopathic phenotype. This work provides insight into PSSM1 pathogenesis and has implications for related human glycogenoses. Public Library of Science 2012-07-31 /pmc/articles/PMC3409190/ /pubmed/22860112 http://dx.doi.org/10.1371/journal.pone.0042317 Text en © 2012 Naylor et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Naylor, Rosie J.
Livesey, Leanda
Schumacher, John
Henke, Nicole
Massey, Claire
Brock, Kenny V.
Fernandez-Fuente, Marta
Piercy, Richard J.
Allele Copy Number and Underlying Pathology Are Associated with Subclinical Severity in Equine Type 1 Polysaccharide Storage Myopathy (PSSM1)
title Allele Copy Number and Underlying Pathology Are Associated with Subclinical Severity in Equine Type 1 Polysaccharide Storage Myopathy (PSSM1)
title_full Allele Copy Number and Underlying Pathology Are Associated with Subclinical Severity in Equine Type 1 Polysaccharide Storage Myopathy (PSSM1)
title_fullStr Allele Copy Number and Underlying Pathology Are Associated with Subclinical Severity in Equine Type 1 Polysaccharide Storage Myopathy (PSSM1)
title_full_unstemmed Allele Copy Number and Underlying Pathology Are Associated with Subclinical Severity in Equine Type 1 Polysaccharide Storage Myopathy (PSSM1)
title_short Allele Copy Number and Underlying Pathology Are Associated with Subclinical Severity in Equine Type 1 Polysaccharide Storage Myopathy (PSSM1)
title_sort allele copy number and underlying pathology are associated with subclinical severity in equine type 1 polysaccharide storage myopathy (pssm1)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409190/
https://www.ncbi.nlm.nih.gov/pubmed/22860112
http://dx.doi.org/10.1371/journal.pone.0042317
work_keys_str_mv AT naylorrosiej allelecopynumberandunderlyingpathologyareassociatedwithsubclinicalseverityinequinetype1polysaccharidestoragemyopathypssm1
AT liveseyleanda allelecopynumberandunderlyingpathologyareassociatedwithsubclinicalseverityinequinetype1polysaccharidestoragemyopathypssm1
AT schumacherjohn allelecopynumberandunderlyingpathologyareassociatedwithsubclinicalseverityinequinetype1polysaccharidestoragemyopathypssm1
AT henkenicole allelecopynumberandunderlyingpathologyareassociatedwithsubclinicalseverityinequinetype1polysaccharidestoragemyopathypssm1
AT masseyclaire allelecopynumberandunderlyingpathologyareassociatedwithsubclinicalseverityinequinetype1polysaccharidestoragemyopathypssm1
AT brockkennyv allelecopynumberandunderlyingpathologyareassociatedwithsubclinicalseverityinequinetype1polysaccharidestoragemyopathypssm1
AT fernandezfuentemarta allelecopynumberandunderlyingpathologyareassociatedwithsubclinicalseverityinequinetype1polysaccharidestoragemyopathypssm1
AT piercyrichardj allelecopynumberandunderlyingpathologyareassociatedwithsubclinicalseverityinequinetype1polysaccharidestoragemyopathypssm1